


AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

LISTING OF CLAIMS:


1. A pyrazole derivative represented by the following general formula:



wherein

R¹ represents a hydrogen atom, a C₁₋₆ alkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (A), a C₂₋₆ alkenyl group which may have the same or different 1 to 3 groups selected from the following substituent group (A), a C₂₋₆ alkynyl group which may have the same or different 1 to 3 groups selected from the following substituent group (A), a C₃₋₈ cycloalkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (A), a C₆₋₁₀ aryl group which may have the same or different 1 to 3 groups selected from the following substituent group (B), a C₂₋₉ heterocycloalkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (A), or a C₁₋₉ heteroaryl group which may have the same or different 1 to 3 groups selected from the following substituent group (B);

one of Q and T represents a group selected from



other represents a group represented by the formula: -Z-Ar wherein Ar represents a C₆₋₁₀ aryl group which may have the same or different 1 to 3 groups selected from the following substituent group (B) or a C₁₋₉ heteroaryl group which may have the same or different 1 to 3 groups selected from the following substituent group (B); and Z represents -O-, -S- or -NY- (in which Y represents a hydrogen atom or a C₁₋₆ alkyl group), an aliphatic cyclic amino group which may have the same or different 1 to 3 groups selected from the following substituent group (A), or an aromatic cyclic amino group which may have the same or different 1 to 3 groups selected from the following substituent group (B);

R represents a C₃₋₈ cycloalkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (A), a C₆₋₁₀ aryl group which may have the same or different 1 to 3 groups selected from the following substituent group (B), a C₂₋₉ heterocycloalkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (A), or a C₁₋₉ heteroaryl group which may have the same or different 1 to 3 groups selected from the following substituent group (B);

[substituent group (A)]:

a halogen atom, a nitro group, a cyano group, an oxo group, -G¹, -OG², -SG², -N(G²)₂, -C(=O)G², -C(=O)OG², -C(=O)N(G²)₂, -S(=O)₂G², -S(=O)₂OG², -S(=O)₂N(G²)₂, -S(=O)G¹, -OC(=O)G¹, -OC(=O)N(G²)₂, -NHC(=O)G², -OS(=O)₂G¹, -NHS(=O)₂G¹ and -C(=O)NHS(=O)₂G¹;

[substituent group (B)]:

a halogen atom, a nitro group, a cyano group, $-G^1$, $-OG^2$, $-SG^2$, $-N(G^2)_2$, $-G^3OG^4$, $-G^3N(G^4)_2$, $-C(=O)G^2$, $-C(=O)OG^2$, $-C(=O)N(G^2)_2$, $-S(=O)_2G^2$, $-S(=O)_2OG^2$, $-S(=O)_2N(G^2)_2$, $-S(=O)G^1$, $-OC(=O)G^1$, $-OC(=O)N(G^2)_2$, $-NHC(=O)G^2$, $-OS(=O)_2G^1$, $-NHS(=O)_2G^1$ and $-C(=O)NHS(=O)_2G^1$;

in the above substituent group (A) and/or (B),

G^1 represents a C_{1-6} alkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C), a C_{2-6} alkenyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C), a C_{2-6} alkynyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C), a C_{3-8} cycloalkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C), a C_{6-10} aryl group which may have the same or different 1 to 3 groups selected from the following substituent group (D), a C_{2-9} heterocycloalkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C), or a C_{1-9} heteroaryl group which may have the same or different 1 to 3 groups selected from the following substituent group (D);

G^2 represents a hydrogen atom, a C_{1-6} alkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C), a C_{2-6} alkenyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C), a C_{2-6} alkynyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C), a C_{3-8} cycloalkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C), a C_{6-10} aryl group which may have the

PRELIMINARY AMENDMENT
PCT/JP2004/008695

same or different 1 to 3 groups selected from the following substituent group (D), a C₂₋₉ heterocycloalkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C), or a C₁₋₉ heteroaryl group which may have the same or different 1 to 3 groups selected from the following substituent group (D), and with the proviso that G² may be the same or different when there are 2 or more G² in the substituents;

G³ represents a C₁₋₆ alkyl group;

G⁴ represents a C₁₋₆ alkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C), and with the proviso that G⁴ may be the same or different when there are 2 or more G⁴ in the substituents;

[substituent group (C)]:

a halogen atom, a nitro group, a cyano group, an oxo group, -G⁵, -OG⁶, -SG⁶, -N(G⁶)₂, -C(=O)G⁶, -C(=O)OG⁶, -C(=O)N(G⁶)₂, -S(=O)₂G⁶, -S(=O)₂OG⁶, -S(=O)₂N(G⁶)₂, -S(=O)G⁵, -OC(=O)G⁵, -OC(=O)N(G⁶)₂, -NHC(=O)G⁶, -OS(=O)₂G⁵, -NHS(=O)₂G⁵ and -C(=O)NHS(=O)₂G⁵; and


[substituent group (D)]:

a halogen atom, a nitro group, a cyano group, -G⁵, -OG⁶, -SG⁶, -N(G⁶)₂, -C(=O)G⁶, -C(=O)OG⁶, -C(=O)N(G⁶)₂, -S(=O)₂G⁶, -S(=O)₂OG⁶, -S(=O)₂N(G⁶)₂, -S(=O)G⁵, -OC(=O)G⁵, -OC(=O)N(G⁶)₂, -NHC(=O)G⁶, -OS(=O)₂G⁵, -NHS(=O)₂G⁵ and -C(=O)NHS(=O)₂G⁵; in the substituent group (C) and/or (D),

G⁵ represents a C₁₋₆ alkyl group, a C₂₋₆ alkenyl group, a C₂₋₆ alkynyl, a C₃₋₈ cycloalkyl group, a C₆₋₁₀ aryl group, a C₂₋₉ heterocycloalkyl group or a C₁₋₉ heteroaryl group; and

G^6 represents a hydrogen atom, a C_{1-6} alkyl group, a C_{2-6} alkenyl group, a C_{2-6} alkynyl, a C_{3-8} cycloalkyl group, a C_{6-10} aryl group, a C_{2-9} heterocycloalkyl group or a C_{1-9} heteroaryl group, and with the proviso that G^6 may be the same or different when there are 2 or more G^6 in the substituents, or a pharmaceutically acceptable salt thereof or a prodrug thereof.

2. A pyrazole derivative as claimed in claim 1, wherein Q represents a group represented by the formula: $-Z-Ar^1$ wherein Ar^1 represents a C_{6-10} aryl group which may have the same or different 1 to 3 groups selected from the following substituent group (B); and Z represents $-O-$, $-S-$ or $-NY-$ (in which Y represents a hydrogen atom or a C_{1-6} alkyl group), an aliphatic cyclic amino group which may have the same or different 1 to 3 groups selected from the following substituent group (A), or an aromatic cyclic amino group which may have the same or different 1 to 3 groups selected from the following substituent group (B); T represents a group selected from



represents a C_{6-10} aryl group which may have the same or different 1 to 3 groups selected from the following substituent group (B);

[substituent group (B)]:

a halogen atom, a nitro group, a cyano group, $-G^1$, $-OG^2$, $-SG^2$, $-N(G^2)_2$, $-G^3OG^4$, $-G^3N(G^4)_2$, $-C(=O)G^2$, $-C(=O)OG^2$, $-C(=O)N(G^2)_2$, $-S(=O)_2G^2$, $-S(=O)_2OG^2$, $-S(=O)_2N(G^2)_2$, $-S(=O)G^1$, $-OC(=O)G^1$, $-OC(=O)N(G^2)_2$, $-NHC(=O)G^2$, $-OS(=O)_2G^1$, $-NHS(=O)_2G^1$ and $-C(=O)NHS(=O)_2G^1$;

PRELIMINARY AMENDMENT
PCT/JP2004/008695

in the above substituent group (B),

G^1 represents a C_{1-6} alkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C), a C_{2-6} alkenyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C), a C_{2-6} alkynyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C), a C_{3-8} cycloalkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C), a C_{6-10} aryl group which may have the same or different 1 to 3 groups selected from the following substituent group (D), a C_{2-9} heterocycloalkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C), or a C_{1-9} heteroaryl group which may have the same or different 1 to 3 groups selected from the following substituent group (D);

G^2 represents a hydrogen atom, a C_{1-6} alkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C), a C_{2-6} alkenyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C), a C_{2-6} alkynyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C), a C_{3-8} cycloalkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C), a C_{6-10} aryl group which may have the same or different 1 to 3 groups selected from the following substituent group (D), a C_{2-9} heterocycloalkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C), or a C_{1-9} heteroaryl group which may have the same or different 1 to 3 groups selected from the following substituent group (D), and with the proviso that G^2 may be the same or different when there are 2 or more G^2 in the substituents;

G^3 represents a C_{1-6} alkyl group;

G^4 represents a C_{1-6} alkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C), and with the proviso that G^4 may be the same or different when there are 2 or more G^4 in the substituents;

[substituent group (C)]:

a halogen atom, a nitro group, a cyano group, an oxo group, $-G^5$, $-OG^6$, $-SG^6$, $-N(G^6)_2$, $-C(=O)G^6$, $-C(=O)OG^6$, $-C(=O)N(G^6)_2$, $-S(=O)_2G^6$, $-S(=O)_2OG^6$, $-S(=O)_2N(G^6)_2$, $-S(=O)G^5$, $-OC(=O)G^5$, $-OC(=O)N(G^6)_2$, $-NHC(=O)G^6$, $-OS(=O)_2G^5$, $-NHS(=O)_2G^5$ and $-C(=O)NHS(=O)_2G^5$; and

[substituent group (D)]:

a halogen atom, a nitro group, a cyano group, $-G^5$, $-OG^6$, $-SG^6$, $-N(G^6)_2$, $-C(=O)G^6$, $-C(=O)OG^6$, $-C(=O)N(G^6)_2$, $-S(=O)_2G^6$, $-S(=O)_2OG^6$, $-S(=O)_2N(G^6)_2$, $-S(=O)G^5$, $-OC(=O)G^5$, $-OC(=O)N(G^6)_2$, $-NHC(=O)G^6$, $-OS(=O)_2G^5$, $-NHS(=O)_2G^5$ and $-C(=O)NHS(=O)_2G^5$; in the substituent group (C) and/or (D),

G^5 represents a C_{1-6} alkyl group, a C_{2-6} alkenyl group, a C_{2-6} alkynyl, a C_{3-8} cycloalkyl group, a C_{6-10} aryl group, a C_{2-9} heterocycloalkyl group or a C_{1-9} heteroaryl group; and

G^6 represents a hydrogen atom, a C_{1-6} alkyl group, a C_{2-6} alkenyl group, a C_{2-6} alkynyl, a C_{3-8} cycloalkyl group, a C_{6-10} aryl group, a C_{2-9} heterocycloalkyl group or a C_{1-9} heteroaryl group, and with the proviso that G^6 may be the same or different when there are 2 or more G^6 in the substituents, or a pharmaceutically acceptable salt thereof or a prodrug thereof.

PRELIMINARY AMENDMENT
PCT/JP2004/008695


3. A pharmaceutical composition comprising as an active ingredient a pyrazole derivative as claimed in claim 1 or 2, or a pharmaceutically acceptable salt thereof or a prodrug thereof.
4. A pharmaceutical composition as claimed in claim 3, wherein the composition is a sodium/glucose cotransporter inhibitor.
5. (currently amended): A pharmaceutical composition as claimed in claim 3 ~~or 4~~, wherein a target disease is a disease caused by excess uptake of at least a kind of carbohydrate selected from glucose, fructose and mannose.
6. A pharmaceutical composition as claimed in claim 5, wherein the target disease is selected from a group consisting of diabetes, postprandial hyperglycemia, impaired glucose tolerance, diabetic complications, obesity, hyperinsulinemia, hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, lipid metabolism disorders, atherosclerosis, hypertension, congestive heart failure, edematous state, metabolic acidosis, syndrome X, hyperuricemia, gout and nephritis.
7. A pharmaceutical composition as claimed ~~in any one of claims 3 to 6~~ in claim 3, which comprises at least one drug selected from the group consisting of an insulin sensitivity enhancer, a glucose absorption inhibitor, a biguanide, an insulin secretion enhancer, a SGLT2 inhibitor, an insulin or insulin analogue, a glucagon receptor antagonist, an insulin receptor kinase stimulant, a tripeptidyl peptidase II inhibitor, a dipeptidyl peptidase IV inhibitor, a protein tyrosine

PRELIMINARY AMENDMENT
PCT/JP2004/008695

phosphatase-1B inhibitor, a glycogen phosphorylase inhibitor, a glucose-6-phosphatase inhibitor, a fructose-bisphosphatase inhibitor, a pyruvate dehydrogenase inhibitor, a hepatic gluconeogenesis inhibitor, D-chiroinsitol, a glycogen synthase kinase-3 inhibitor, glucagon-like peptide-1, a glucagon-like peptide-1 analogue, a glucagon-like peptide-1 agonist, amylin, an amylin analogue, an amylin agonist, an aldose reductase inhibitor, an advanced glycation endproducts formation inhibitor, a protein kinase C inhibitor, a α -aminobutyric acid receptor antagonist, a sodium channel antagonist, a transcript factor NF- κ B inhibitor, a lipid peroxidase inhibitor, an *N*-acetylated- α -linked-acid-dipeptidase inhibitor, insulin-like growth factor-I, platelet-derived growth factor, a platelet-derived growth factor analogue, epidermal growth factor, nerve growth factor, a carnitine derivative, uridine, 5-hydroxy-1-methylhydantoin, EGB-761, bimoclomol, sulodexide, Y-128, a hydroxymethylglutaryl coenzyme A reductase inhibitor, a fibric acid derivative, a α_3 -adrenoceptor agonist, an acyl-coenzyme A cholesterol acyltransferase inhibitor, probcol, a thyroid hormone receptor agonist, a cholesterol absorption inhibitor, a lipase inhibitor, a microsomal triglyceride transfer protein inhibitor, a lipoxxygenase inhibitor, a carnitine palmitoyl-transferase inhibitor, a squalene synthase inhibitor, a low-density lipoprotein receptor enhancer, a nicotinic acid derivative, a bile acid sequestrant, a sodium/bile acid cotransporter inhibitor, a cholesterol ester transfer protein inhibitor, an appetite suppressant, an angiotensin-converting enzyme inhibitor, a neutral endopeptidase inhibitor, an angiotensin II receptor antagonist, an endothelin-converting enzyme inhibitor, an endothelin receptor antagonist, a diuretic agent, a calcium antagonist, a vasodilating antihypertensive agent, a sympathetic blocking agent, a centrally acting antihypertensive agent, an α_2 -adrenoceptor

agonist, an antiplatelets agent, a uric acid synthesis inhibitor, a uricosuric agent and a urinary alkalinizer.


8. A pyrazole derivative represented by the general formula:



wherein

R^{1A} represents a hydrogen atom, a C_{1-6} alkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (A1), a C_{2-6} alkenyl group which may have the same or different 1 to 3 groups selected from the following substituent group (A1), a C_{2-6} alkynyl group which may have the same or different 1 to 3 groups selected from the following substituent group (A1), a C_{3-8} cycloalkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (A1), a C_{6-10} aryl group which may have the same or different 1 to 3 groups selected from the following substituent group (B1), a C_{2-9} heterocycloalkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (A1), or a C_{1-9} heteroaryl group which may have the same or different 1 to 3 groups selected from the following substituent group (B1);

one of Q^A and T^A represents a group selected from



has a protective group, and the other represents a group represented by the formula: $-Z^A-Ar^A$ wherein Ar^A represents a C_{6-10} aryl group which may have the same or different 1 to 3 groups selected from the following substituent group (B1) or a C_{1-9} heteroaryl group which may have the same or different 1 to 3 groups selected from the following substituent group (B1); and Z^A represents $-O-$, $-S-$ or $-NY^A-$ (in which Y^A represents a hydrogen atom, a C_{1-6} alkyl group or a protective group), an aliphatic cyclic amino group which may have the same or different 1 to 3 groups selected from the following substituent group (A1), or an aromatic cyclic amino group which may have the same or different 1 to 3 groups selected from the following substituent group (B1);

R^A represents a C_{3-8} cycloalkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (A1), a C_{6-10} aryl group which may have the same or different 1 to 3 groups selected from the following substituent group (B1), a C_{2-9} heterocycloalkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (A1), or a C_{1-9} heteroaryl group which may have the same or different 1 to 3 groups selected from the following substituent group (B1);
[substituent group (A1)]:

a halogen atom, a nitro group, a cyano group, an oxo group, $-G^{1A}$, $-OG^{2B}$, $-SG^{2B}$, $-N(G^{2B})_2$, $-C(=O)G^{2A}$, $-C(=O)OG^{2B}$, $-C(=O)N(G^{2B})_2$, $-S(=O)_2G^{2A}$, $-S(=O)_2OG^{2A}$, $-S(=O)_2N(G^{2B})_2$,

$-S(=O)G^{1A}$, $-OC(=O)G^{1A}$, $-OC(=O)N(G^{2B})_2$, $-NHC(=O)G^{2A}$, $-OS(=O)_2G^{1A}$, $-NHS(=O)_2G^{1A}$ and $-C(=O)NHS(=O)_2G^{1A}$;

[substituent group (B1)]:

a halogen atom, a nitro group, a cyano group, $-G^{1A}$, $-OG^{2B}$, $-SG^{2B}$, $-N(G^{2B})_2$, $-G^3OG^{4A}$, $-G^3N(G^{4A})_2$, $-C(=O)G^{2A}$, $-C(=O)OG^{2B}$, $-C(=O)N(G^{2B})_2$, $-S(=O)_2G^{2A}$, $-S(=O)_2OG^{2A}$, $-S(=O)_2N(G^{2B})_2$, $-S(=O)G^{1A}$, $-OC(=O)G^{1A}$, $-OC(=O)N(G^{2B})_2$, $-NHC(=O)G^{2A}$, $-OS(=O)_2G^{1A}$, $-NHS(=O)_2G^{1A}$ and $-C(=O)NHS(=O)_2G^{1A}$;

in the above substituent group (A1) and/or (B1),

G^{1A} represents a C_{1-6} alkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C1), a C_{2-6} alkenyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C1), a C_{2-6} alkynyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C1), a C_{3-8} cycloalkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C1), a C_{6-10} aryl group which may have the same or different 1 to 3 groups selected from the following substituent group (D1), a C_{2-9} heterocycloalkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C1), or a C_{1-9} heteroaryl group which may have the same or different 1 to 3 groups selected from the following substituent group (D1);

G^{2A} represents a hydrogen atom, a C_{1-6} alkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C1), a C_{2-6} alkenyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C1), a C_{2-6} alkynyl group which may have the same or different 1 to 3 groups selected

from the following substituent group (C1), a C₃₋₈ cycloalkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C1), a C₆₋₁₀ aryl group which may have the same or different 1 to 3 groups selected from the following substituent group (D1), a C₂₋₉ heterocycloalkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C1), or a C₁₋₉ heteroaryl group which may have the same or different 1 to 3 groups selected from the following substituent group (D1);

G^{2B} represents a protective group, a hydrogen atom, a C₁₋₆ alkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C1), a C₂₋₆ alkenyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C1), a C₂₋₆ alkynyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C1), a C₃₋₈ cycloalkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C1), a C₆₋₁₀ aryl group which may have the same or different 1 to 3 groups selected from the following substituent group (D1), a C₂₋₉ heterocycloalkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C1), or a C₁₋₉ heteroaryl group which may have the same or different 1 to 3 groups selected from the following substituent group (D1); and with the proviso that G^{2B} may be the same or different when there are 2 or more G^{2B} in the substituents;

G³ represents a C₁₋₆ alkyl group;

G^{4A} represents a C₁₋₆ alkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C1), and with the proviso that G^{4A} may be the same or different when there are 2 or more G^{4A} in the substituents;

PRELIMINARY AMENDMENT
PCT/JP2004/008695

[substituent group (C1)]:

a halogen atom, a nitro group, a cyano group, an oxo group, $-G^5$, $-OG^{6A}$, $-SG^{6A}$, $-N(G^{6A})_2$, $-C(=O)G^6$, $-C(=O)OG^{6A}$, $-C(=O)N(G^{6A})_2$, $-S(=O)_2G^6$, $-S(=O)_2OG^6$, $-S(=O)_2N(G^{6A})_2$, $-S(=O)G^5$, $-OC(=O)G^5$, $-OC(=O)N(G^{6A})_2$, $-NHC(=O)G^6$, $-OS(=O)_2G^5$, $-NHS(=O)_2G^5$ and $-C(=O)NHS(=O)_2G^5$; and

[substituent group (D1)]:


a halogen atom, a nitro group, a cyano group, $-G^5$, $-OG^{6A}$, $-SG^{6A}$, $-N(G^{6A})_2$, $-C(=O)G^6$, $-C(=O)OG^{6A}$, $-C(=O)N(G^{6A})_2$, $-S(=O)_2G^6$, $-S(=O)_2OG^6$, $-S(=O)_2N(G^{6A})_2$, $-S(=O)G^5$, $-OC(=O)G^5$, $-OC(=O)N(G^{6A})_2$, $-NHC(=O)G^6$, $-OS(=O)_2G^5$, $-NHS(=O)_2G^5$ and $-C(=O)NHS(=O)_2G^5$;
in the substituent group (C1) and/or (D1),

G^5 represents a C_{1-6} alkyl group, a C_{2-6} alkenyl group, a C_{2-6} alkynyl, a C_{3-8} cycloalkyl group, a C_{6-10} aryl group, a C_{2-9} heterocycloalkyl group or a C_{1-9} heteroaryl group; and

G^6 represents a hydrogen atom, a C_{1-6} alkyl group, a C_{2-6} alkenyl group, a C_{2-6} alkynyl, a C_{3-8} cycloalkyl group, a C_{6-10} aryl group, a C_{2-9} heterocycloalkyl group or a C_{1-9} heteroaryl group;

G^{6A} represents a protective group, a hydrogen atom, a C_{1-6} alkyl group, a C_{2-6} alkenyl group, a C_{2-6} alkynyl, a C_{3-8} cycloalkyl group, a C_{6-10} aryl group, a C_{2-9} heterocycloalkyl group or a C_{1-9} heteroaryl group, and with the proviso that G^{6A} may be the same or different when there are 2 or more G^{6A} in the substituents, or a pharmaceutically acceptable salt thereof.

9. A pyrazole derivative represented by the general formula:



wherein

R^{1A} represents a hydrogen atom, a C₁₋₆ alkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (A1), a C₂₋₆ alkenyl group which may have the same or different 1 to 3 groups selected from the following substituent group (A1), a C₂₋₆ alkynyl group which may have the same or different 1 to 3 groups selected from the following substituent group (A1), a C₃₋₈ cycloalkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (A1), a C₆₋₁₀ aryl group which may have the same or different 1 to 3 groups selected from the following substituent group (B1), a C₂₋₉ heterocycloalkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (A1), or a C₁₋₉ heteroaryl group which may have the same or different 1 to 3 groups selected from the following substituent group (B1);

one of Q^B and T^B represents a hydroxy group, and the other represents a group represented by the formula: -Z^A-Ar^A wherein Ar^A represents a C₆₋₁₀ aryl group which may have the same or different 1 to 3 groups selected from the following substituent group (B1) or a C₁₋₉ heteroaryl group which may have the same or different 1 to 3 groups selected from the following substituent group (B1); and Z^A represents -O-, -S- or -NY^A- (in which Y^A represents a hydrogen atom, a C₁₋₆ alkyl group or a protective group), an aliphatic cyclic amino group which may have the same or different 1 to 3 groups selected from the following substituent group (A1), or an

PRELIMINARY AMENDMENT
PCT/JP2004/008695

aromatic cyclic amino group which may have the same or different 1 to 3 groups selected from the following substituent group (B1);

R^A represents a C_{3-8} cycloalkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (A1), a C_{6-10} aryl group which may have the same or different 1 to 3 groups selected from the following substituent group (B1), a C_{2-9} heterocycloalkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (A1), or a C_{1-9} heteroaryl group which may have the same or different 1 to 3 groups selected from the following substituent group (B1);

[substituent group (A1)]:

a halogen atom, a nitro group, a cyano group, an oxo group, $-G^{1A}$, $-OG^{2B}$, $-SG^{2B}$, $-N(G^{2B})_2$, $-C(=O)G^{2A}$, $-C(=O)OG^{2B}$, $-C(=O)N(G^{2B})_2$, $-S(=O)_2G^{2A}$, $-S(=O)_2OG^{2A}$, $-S(=O)_2N(G^{2B})_2$, $-S(=O)G^{1A}$, $-OC(=O)G^{1A}$, $-OC(=O)N(G^{2B})_2$, $-NHC(=O)G^{2A}$, $-OS(=O)_2G^{1A}$, $-NHS(=O)_2G^{1A}$ and $-C(=O)NHS(=O)_2G^{1A}$;

[substituent group (B1)]:

a halogen atom, a nitro group, a cyano group, $-G^{1A}$, $-OG^{2B}$, $-SG^{2B}$, $-N(G^{2B})_2$, $-G^3OG^{4A}$, $-G^3N(G^{4A})_2$, $-C(=O)G^{2A}$, $-C(=O)OG^{2B}$, $-C(=O)N(G^{2B})_2$, $-S(=O)_2G^{2A}$, $-S(=O)_2OG^{2A}$, $-S(=O)_2N(G^{2B})_2$, $-S(=O)G^{1A}$, $-OC(=O)G^{1A}$, $-OC(=O)N(G^{2B})_2$, $-NHC(=O)G^{2A}$, $-OS(=O)_2G^{1A}$, $-NHS(=O)_2G^{1A}$ and $-C(=O)NHS(=O)_2G^{1A}$;

in the above substituent group (A1) and/or (B1),

G^{1A} represents a C_{1-6} alkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C1), a C_{2-6} alkenyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C1), a C_{2-6} alkynyl

group which may have the same or different 1 to 3 groups selected from the following substituent group (C1), a C₃₋₈ cycloalkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C1), a C₆₋₁₀ aryl group which may have the same or different 1 to 3 groups selected from the following substituent group (D1), a C₂₋₉ heterocycloalkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C1), or a C₁₋₉ heteroaryl group which may have the same or different 1 to 3 groups selected from the following substituent group (D1);

G^{2A} represents a hydrogen atom, a C₁₋₆ alkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C1), a C₂₋₆ alkenyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C1), a C₂₋₆ alkynyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C1), a C₃₋₈ cycloalkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C1), a C₆₋₁₀ aryl group which may have the same or different 1 to 3 groups selected from the following substituent group (D1), a C₂₋₉ heterocycloalkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C1), or a C₁₋₉ heteroaryl group which may have the same or different 1 to 3 groups selected from the following substituent group (D1);

G^{2B} represents a protective group, a hydrogen atom, a C₁₋₆ alkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C1), a C₂₋₆ alkenyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C1), a C₂₋₆ alkynyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C1), a C₃₋₈ cycloalkyl group which may have the

same or different 1 to 3 groups selected from the following substituent group (C1), a C₆₋₁₀ aryl group which may have the same or different 1 to 3 groups selected from the following substituent group (D1), a C₂₋₉ heterocycloalkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C1), or a C₁₋₉ heteroaryl group which may have the same or different 1 to 3 groups selected from the following substituent group (D1); and with the proviso that G^{2B} may be the same or different when there are 2 or more G^{2B} in the substituents;

G³ represents a C₁₋₆ alkyl group;

G^{4A} represents a C₁₋₆ alkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C1), and with the proviso that G^{4A} may be the same or different when there are 2 or more G^{4A} in the substituents;

[substituent group (C1)]:

a halogen atom, a nitro group, a cyano group, an oxo group, -G⁵, -OG^{6A}, -SG^{6A}, -N(G^{6A})₂, -C(=O)G⁶, -C(=O)OG^{6A}, -C(=O)N(G^{6A})₂, -S(=O)₂G⁶, -S(=O)₂OG⁶, -S(=O)₂N(G^{6A})₂, -S(=O)G⁵, -OC(=O)G⁵, -OC(=O)N(G^{6A})₂, -NHC(=O)G⁶, -OS(=O)₂G⁵, -NHS(=O)₂G⁵ and -C(=O)NHS(=O)₂G⁵; and

[substituent group (D1)]:

a halogen atom, a nitro group, a cyano group, -G⁵, -OG^{6A}, -SG^{6A}, -N(G^{6A})₂, -C(=O)G⁶, -C(=O)OG^{6A}, -C(=O)N(G^{6A})₂, -S(=O)₂G⁶, -S(=O)₂OG⁶, -S(=O)₂N(G^{6A})₂, -S(=O)G⁵, -OC(=O)G⁵, -OC(=O)N(G^{6A})₂, -NHC(=O)G⁶, -OS(=O)₂G⁵, -NHS(=O)₂G⁵ and -C(=O)NHS(=O)₂G⁵;

in the substituent group (C1) and/or (D1),

G⁵ represents a C₁₋₆ alkyl group, a C₂₋₆ alkenyl group, a C₂₋₆ alkynyl, a C₃₋₈ cycloalkyl group, a C₆₋₁₀ aryl group, a C₂₋₉ heterocycloalkyl group or a C₁₋₉ heteroaryl group;

G⁶ represents a hydrogen atom, a C₁₋₆ alkyl group, a C₂₋₆ alkenyl group, a C₂₋₆ alkynyl, a C₃₋₈ cycloalkyl group, a C₆₋₁₀ aryl group, a C₂₋₉ heterocycloalkyl group or a C₁₋₉ heteroaryl group; and

G^{6A} represents a protective group, a hydrogen atom, a C₁₋₆ alkyl group, a C₂₋₆ alkenyl group, a C₂₋₆ alkynyl, a C₃₋₈ cycloalkyl group, a C₆₋₁₀ aryl group, a C₂₋₉ heterocycloalkyl group or a C₁₋₉ heteroaryl group, and with the proviso that G^{6A} may be the same or different when there are 2 or more G^{6A} in the substituents, or a pharmaceutically acceptable salt thereof.